Week in Review: WuXi PharmaTech and PRA Form Clinical CRO JV
WuXi PharmaTech is forming a JV with PRA, a US-based clinical-stage CRO, that will offer Phase I-IV clinical trial services in China; ShangPharma agreed to a go-private offer from its Founder and TPG group that values the CRO at $173 million; Guangzhou Techpool Bio-Pharma in-licensed the China rights to Bondronat, an oncology drug from Roche; AstraZeneca will collaborate with Fudan University to discover the mechanism behind a TCM product used to treat cardiovascular problems; and Omega Diagnostics, a Scottish test-maker, won approval from the SFDA to market its food allergy test in China. More details…. Stock Symbols: (NYSE: WX) (NYSE: SHP) (VS: ROG) (NYSE: AZN) Share this with colleagues: // //  
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here